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Abstract 
Purpose: In this study, we aimed to investigate the effect of morphine on activation of 
extracellular signal-regulated kinase (ERK) and nuclear factor-B (NF-B), both of which 
play crucial roles in T cell activation. 
Methods: Human CD3+ T cells and Jurkat T cells were stimulated by anti-CD3 antibody or 
phorbol 12-myristate 13-acetate plus ionomycin with or without 24-h pretreatment with 
morphine. Activation of ERK was assessed by immunoblot analysis of phosphorylated ERK. 
Activation of the NF-B signaling pathway was examined by analyzing nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IB)phosphorylation 
using immunoblotting, and interleukin-2 (IL-2) gene expression using quantitative real-time 
reverse-transcriptase polymerase chain reaction. 
Results: Morphine pretreatment enhanced ERK phosphorylation, but inhibited IB 
phosphorylation and IL-2 gene expression in activated T cells. The effects of morphine on 
ERK phosphorylation and IL-2 gene expression were not antagonized by naloxone. We 
detected -opioid receptor transcript in T cells, but U50,488, a -receptor-selective agonist, 
did not enhance ERK phosphorylation. 
Conclusion: Morphine enhances ERK signaling, whereas it inhibits NF-B signaling in 




     Morphine is one of the opioid analgesic drugs which play important roles in 
perioperative settings.  Opioids reduce preoperative anxiety, decrease somatic and autonomic 
responses to airway manipulations, improve intraoperative hemodynamic stability, lower 
requirements for anesthetics, and provide postoperative analgesia [1].  On the other hand, 
morphine administration results in severe immune suppression, and thus may pose a 
significant risk factor for opportunistic infections such as tuberculosis, human 
immunodeficiency virus infection, and pneumonia [2,3].  Although many studies have 
provided overwhelming evidence for morphine-induced changes in immune parameters [3], 
the mechanisms by which these effects are mediated are still to be conclusively determined.  
Two major mechanisms have been implicated; a direct mechanism in which opioids bind to 
receptors on immune cells and directly modulate the function of these cells [4-7], and an 
indirect mechanism in which opioids bind to opioid receptors in the central nervous system, 
causing the release of catecholamines and steroids, which then affect the functioning of 
immune cells [8,9]. 
     Chronic treatment with morphine has been shown to affect the function of T cells, which 
play a crucial role in the defense against nosocomial infection [10].  Chronic morphine 
treatment results in a decrease in CD4+/CD8+ population [11], reduction in proliferative 
response of T cells [12], and induction of differentiation into type 2 helper T cells (Th2) [13].  
It is well known that the T cell receptor (TCR) engagement induces activation of multiple 
signal transduction pathways, including the mitogen-activated protein-kinase (MAPK) 
pathways and nuclear factor-B (NF-B) pathway.  A possible target for modulation by 
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morphine among MAPK pathways might be the extracellular signal-regulated kinase (ERK), 
which is activated rapidly through threonine and tyrosine phosphorylation following TCR 
engagement.  ERK is an important participant in the regulation of cell proliferation and 
differentiation by phosphorylation of a number of intracellular proteins, including 
transcription factors and protein kinases [14].  In T cells, ERK plays crucial roles in T-cell 
maturation and differentiation [15,16].  Modulation of the ERK signaling pathway may cause 
changes in T cell functions, and therefore susceptibility to infection.  NF-B is activated 
through phosphorylation and degradation of nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha (IB) following TCR engagement, and induces 
transcription from many inflammatory genes, including those encoding inflammatory 
cytokines and regulatory chemokines [17].  Although modulation of ERK and NF-B 
signaling pathways by morphine has been demonstrated in activated murine T cells [18], the 
effect of morphine on these signal transduction pathways in activated human T cells is not 
known.  In this investigation, we aimed to determine the direct effect of morphine on ERK 
and NF-B signaling pathways in activated human T cells. 
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Materials and Methods 
 
Materials 
     The human leukemic T cell line, Jurkat, was obtained from American Type Culture 
Collection (Manassas, VA).  The culture medium and other cell culture products were 
obtained from Sigma (St. Louis, MO).  Human placenta total RNA was purchased from 
Clontech (Mountain View, CA).  Morphine hydrochloride was purchased from Takeda 
(Osaka, Japan).  Phorbol 12-myristate 13-acetate (PMA), ionomycin, naloxone hydrochloride, 
and U50,488 were purchased from Sigma. HIT3a (anti-human CD3 monoclonal antibody) 
was purchased from BD Biosciences (Franklin Lakes, NJ).  Mouse monoclonal antibody 
against phospho-IB and rabbit polyclonal antibodies against human phosphorylated 
ERK1/2 and ERK1/2 were purchased from Cell Signaling Technology (Danvers, MA).  
Rabbit polyclonal antibody against -actin was purchased from BioLegend (San Diego, CA).  
Horseradish peroxidase-conjugated sheep anti-mouse and donkey anti-rabbit IgGs were 
purchased from GE Healthcare Bioscience (Uppsala, Sweden). 
 
Cell Culture and Treatment 
     Blood was collected from healthy adult volunteers from Kyoto University after 
informed consent was obtained, and the protocols were reviewed and approved by the 
appropriate Investigative Review Boards.  Peripheral blood mononuclear cells were isolated 
by density-gradient centrifugation using Ficoll-Paque™ PLUS (GE healthcare Bioscience), 
and CD3+ T cells were subsequently purified using a Pan T Cell Isolation Kit II (Miltenyi 
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Biotec, Bergisch Gladbach, Germany) following the manufacturer’s protocol.  Purification of 
CD3+ T cells was conducted using autoMACS (Miltenyi Biotec).  CD3+ T cells and Jurkat T 
cells were cultured in RPMI1640 medium supplemented with 2 mM L-glutamine, 10 mM 
HEPES, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 1 mM sodium pyruvate, 10% fetal 
bovine serum, and 1% penicillin/streptomycin. Cells were incubated at 37 °C in a 5% CO2 
atmosphere. 
     Isolated human CD3+ T cells (10
7
 cells each) or Jurkat T cells (10
6
 cells each) were 
pretreated with morphine or U50,488 for 24 h.  When indicated, cells were treated with 
naloxone 15 min prior to morphine.  After the pretreatment, cells were washed with 
phosphate buffered saline and resuspended in 1 ml of culture medium.  Cells were 
subsequently stimulated with HIT3a (2 μg/ml) or PMA (20 ng/ml) plus ionomycin (100 
ng/ml) for indicated times. 
 
Immunoblot Analysis 
     Cells were collected by 30-sec centrifugation at 4 °C and 4,000 g and resuspended in 
NP40 lysis buffer [1% NP40, 150 mM NaCl, 50 mM Tris-Cl (pH 7.5), Halt™ Protease 
Inhibitor Cocktail (Pierce Biotechnology, Inc., Rockford, IL), and phosphatase inhibitor 
cocktail (Nacalai Tesque, Inc., Kyoto, Japan)].  After 30-min incubation on ice, whole-cell 
lysates were prepared by 5-min centrifugation at 4 °C and 15,000 g.  In each experiment, 
samples were used at equal amounts of total protein, which ranged from 30 to 50 g.  
Proteins were separated by 10% sodium-dodecyl-sulfate polyacrylamide gel electrophoresis 
and electrophoretically transferred to polyvinylidene difluoride membranes.  Membranes 
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were incubated with primary antibodies for phosphorylated ERK, phosphorylated IB, total 
ERK, or -actin at 1:1,000 dilution followed by horseradish peroxidase-conjugated secondary 
antibodies at 1:20,000 dilution.  To quantify phosphorylated ERK or IB, total ERK or -
actin was assessed by imunoblot analysis using the same membrane after stripping.  
Membranes were stripped by incubation in stripping buffer (2% sodium dodecyl sulfate, 62.5 
mM Tris-HCl pH 6.8, 0.8% -mercaptoethanol) at 50 °C for 30 min and rinsed with Tris 
buffered saline containing 0.05% Tween20. Immunoreactive bands were visualized using 
chemiluminescence (ECL plus, GE healthcare Bioscience).  The quantity of the 
immunoreactive bands was determined by densitometry using ImageJ (provided by National 
Institutes of Health).  Phosphorylated ERK or IB levels in PMA/ionomycin- or HIT3a-
stimulated cells without pretreatment were defined as controls, and the amount of 
phosphorylated ERK or IB was expressed as a percentage of the control. 
 
Total RNA Isolation 
     After collecting cells by 30-sec centrifugation at 4 °C and 4,000 g, total RNA was 
isolated using an illustra RNAspin Mini RNA isolation Kit (GE Healthcare Bioscience) 
according to the manufacturer’s instructions and dissolved in diethyl pyrocarbonate-treated 
water.  The RNA was quantified by A260 measurement. 
 
Reverse-transcriptase Polymerase-chain-reaction (RT-PCR), Cloning of PCR Products, and 
DNA Sequence Analysis 
     Complementary DNA (cDNA) was synthesized from 1 g total RNA using a 
SuperScriptIII First-Strand Synthesis System for RT-PCR (Invitrogen) according to the 
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system protocol.  One fiftieth of the synthesized cDNA was amplified using the Platinum® 
Taq DNA polymerase HighFidelity (Invitrogen).  The amplification was performed in a 
GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA).  The nucleotide 
sequences of the primers for  opioid receptor were 5’- 
AAAGTCAGGGAAGACGTCGATGTC -3’ and 5’- 
GAATGGGATTCAGGCTACTGTTGG -3’ (described previously [19]).  After an initial 3-
min incubation at 95 °C, cDNA was amplified for 40 cycles (95 °C for 20 sec, 59 °C for 30 
sec, 72 °C for 30 sec).  PCR products were separated on 1.5% agarose gel containing 0.1 
g/ml ethidium bromide and photographed under ultra-violet illumination. 
     After separation on agarose gel, the main band was excised by TaKaRa RECOCHIP 
(Takara Bio inc., Otsu, Japan).  The PCR products were cloned into pGEM®-T Easy vector 
(Promega, Madison, WI ) and sequenced using a Big Dye Terminator Sequencing Kit (Perkin-
Elmer, Foster City, CA) and an ABI 377 sequencer (Applied Biosystems).  Sequence data 
was analyzed with Sequencher 3.1 (Gene Codes, Ann Arbor, MA). 
 
Quantitative Real-Time RT-PCR 
     For quantitative real-time RT-PCR, 100 ng of total RNA was used as a template.  First-
strand synthesis and real-time PCR reaction was performed using a QuantiTect SYBR Green 
PCR Kit™ (Qiagen Inc., Germantown, MD) following a protocol provided by the company.  
PCR reaction and detection was performed using an Applied Biosystems 7300 real time PCR 
system.  PCR primers were purchased from Qiagen Inc.  The fold change in expression of 





     Results are expressed as percentages of the controls in means and standard deviations.   
In all experiments, the normality of the data was tested using Shapiro-Wilks test and the null 
hypothesis was not rejected.  Comparisons between two groups were performed with 
Student’s t-test.  Multiple comparisons were performed with one-way ANOVA followed by 





Effect of Morphine on ERK Phosphorylation in Stimulated CD3+ T Cells and Jurkat T Cells 
     Stimulation with anti-CD3 antibody for 5 min induced ERK phosphorylation in CD3+ T 
cells. Pretreatment of CD3+ T cells with morphine significantly enhanced ERK 
phosphorylation induced by anti-CD3 antibody (Fig. 1A).  Similarly, in Jurkat T cells, 
stimulation with anti-CD3 antibody for 5 min induced ERK phosphorylation, and morphine 
pretreatment enhanced ERK phosphorylation (Fig. 1B).  In contrast, 24-h morphine treatment 
alone did not induce ERK phosphorylation in Jurkat T cells (Fig. 1B). 
     Next we examined the effect of morphine on ERK phosphorylation induced by PMA 
plus ionomycin (PMA/Io).  Stimulation with PMA/Io mimics the T-cell-receptor-induced T 
cell activation by directly activating protein kinase C (PKC) and increasing the intracellular 
calcium concentration.  In PMA/Io-stimulated Jurkat T cells, the band of phosphorylated 
ERK appeared within 5 min and lasted for more than 30 min (Fig. 2A).  Morphine 
pretreatment for 24 h enhanced ERK phosphorylation induced by PMA/Io, whereas 24 h 
morphine treatment alone did not induce ERK phosphorylation (Fig. 2A).  To determine the 
dependence of ERK signaling enhancement on morphine concentration, we pretreated Jurkat 
T cells with different concentrations of morphine and subsequently stimulated them with 
PMA/Io.  Although 10 nM of morphine did not have a significant effect, 1 M was sufficient 
to enhance ERK phosphorylation (Fig. 2B). 
     We previously reported that opioid receptors expressed in cultured cells activate ERK 
[20].  It was also reported that morphine induces ERK phosphorylation in the human 
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lymphocytic cell line, CEMx174 [21].  In the present study, ERK phosphorylation was not 
detectable in Jurkat T cells treated with morphine for 24 h (Fig. 1B and 2A).  However, these 
results cannot exclude morphine-induced ERK phosphorylation, because ERK 
phosphorylation mediated by opioid receptors peaks within 15 min [20].  To determine 
whether morphine by itself induces ERK phosphorylation, we treated Jurkat T cells with 100 
M morphine for 5 to 60 min, but did not detect any ERK phosphorylation (Fig. 3). 
 
Opioid Receptors are not Involved in the Effect of Morphine on ERK Signaling in Activated T 
Cells 
     To clarify whether the effect of morphine on the ERK signaling pathway is mediated by 
opioid receptors, we tested the effect of naloxone, which can inhibit all types of the opioid 
receptor, on the enhancement of ERK phosphorylation by morphine.  Fig. 4A shows that 
enhancement of PMA/Io-induced ERK phosphorylation by 1 M morphine was not 
significantly suppressed by 10 M naloxone. 
      Opioid receptors are classified into three types, , , and  (MOR, DOR and KOR, 
respectively).  To clarify whether Jurkat T cells express these types of opioid receptors, we 
examined mRNA expression of these receptors using RT-PCR.  Although transcripts for 
MOR and DOR could not be detected (data not shown), we detected KOR transcript in Jurkat 
T cells (Fig. 4B).  The nucleotide sequence of the PCR product from Jurkat T cells showed 
100% homology with that from human placenta and the cDNA sequence of KOR from human 
brain (GenBank accession no. L37362) (data not shown).  To determine whether KOR 
mediate the enhancement of ERK phosphorylation in activated T cells, we examined the 
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effect of U50,488, a -specific agonist, on ERK phosphorylation.  Pretreatment of Jurkat T 
cells with U50,488 had no effect on PMA/Io-induced ERK phosphorylation (Fig. 4C). 
 
Effect of Morphine on IB Phosphorylation and IL-2 Gene Expression in Activated T Cells 
     Activation of TCR leads to activation of not only ERK but also NF-B [22].  TCR 
stimulation leads to activation of an IB kinase (IKK) complex through diacylglycerol (DAG) 
production followed by activation of PKC.  Activated IKK complex in turn induces 
phosphorylation and degradation of IB, resulting in NF-B activation.  Inhibition of NF-
B activation by morphine has been demonstrated in murine T cells [18], but in human T cells 
the effect of morphine on the NF- B pathway is not known. 
     To test the effect of morphine on signal transduction through the NF-B pathway in 
activated T cells, we investigated the effect of morphine on IB phosphorylation.  In 
preliminary experiments, we examined the time course of IB phosphorylation induced by 
PMA/Io.  After PMA/Io stimulation, the band of phosphorylated IB appeared at 5 min, 
peaked at 15 min, and disappeared at 30 min (data not shown).  Accordingly, we thereafter 
stimulated cells for 15 min to examine the effect of morphine on IB phosphorylation.  As 
shown in Fig. 5A, pretreatment of Jurkat T cells with morphine significantly inhibited 
PMA/Io-induced IB phosphorylation. 
     IL-2 is a pivotal cytokine involved in T cell regulation, proliferation, and host defense 
mechanisms [23], and its expression is regulated by multiple transcription factors including 
NF-B [24].  To determine the effect of morphine on IL-2 production in activated T cells, we 
pretreated Jurkat T cells with morphine and examined its effect on IL-2 gene expression after 
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stimulation.  IL-2 gene expression induced by PMA/Io was suppressed by morphine in a 
dose-dependent manner (Fig. 5B).  Naloxone did not antagonize the inhibitory effect of 




     In this investigation, we demonstrated that pretreatment with morphine enhances ERK 
phosphorylation, but suppresses IB phosphorylation and IL-2 gene expression in activated 
human T cells.  These responses were not significantly antagonized by naloxone.  To our 
knowledge, this is the first report of dual modulation of the T cell receptor-activated signal 
transduction pathway by morphine in human T lymphocytes. 
     While Chuang et al. demonstrated that morphine induces ERK phosphorylation in a 
human lymphocytic cell line, CEMx174 [21], morphine by itself did not induce ERK 
phosphorylation in Jurkat T cells in this study.  This apparent inconsistency might be 
explained by the absence of functional opioid receptors or an ERK activation pathway linked 
with the opioid receptors in Jurkat T cells.  The lack of ERK phosphorylation following 
stimulation by morphine for 5-60 min or 24 h suggests that the potentiating effect of morphine 
on ERK phosphorylation in activated T cells is not through direct activation of the ERK 
signaling pathway but by indirect modulation of signal transduction.  TCR stimulation results 
in activation of ERK through two different pathways [25] (Fig. 6).  One pathway is through 
Growth factor receptor-bound protein 2 (Grb2) and Son of sevenless (SOS), which is 
analogous to what has been observed for Ras-mediated ERK activation triggered by 
stimulation of growth factor receptors [26].  The other pathway is through activation of Ras 
guanyl nucleotide-releasing protein (RasGRP) by DAG.  Although the mechanism by which 
DAG activates RasGRP remains to be established, involvement of a novel PKC subfamily 
(PKC , , , ) is suggested.  We have demonstrated that morphine enhances ERK 
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phosphorylation induced by stimulation with PMA/Io as well as anti-CD3 antibody.  This 
result suggests that the potentiating effect of morphine on ERK phosphorylation is through 
modulation of the signaling pathway downstream of DAG, because PMA, a synthetic DAG 
analogue, activates ERK by PKC activation. 
     We have demonstrated that morphine inhibits IL-2 gene expression in activated T cells.  
Since IL-2 plays a crucial role for T cell activation and proliferation [23], inhibition of IL-2 
expression may at least partly explain the immunosuppression by morphine.  We also showed 
inhibition of IB phosphorylation by morphine, which may represent a mechanism of 
inhibition of IL-2 expression.  Although the NF-B pathway and ERK signaling pathway 
have a common upstream signaling pathway including DAG and PKC in T cells [27,28], 
morphine inhibited PMA/Io-induced IB phosphorylation, whereas it enhanced PMA/Io-
induced ERK phosphorylation.  These results indicate that morphine has opposite effects on 
the two signal transduction pathways downstream of DAG: an inhibitory effect on the DAG-
PKC-NF-B pathway, and augmentation of the DAG-PKC-RasGRP-Ras-ERK pathway. 
     The enhancement of the ERK signaling pathway by morphine shown in this study may 
be involved in the mechanisms of morphine-induced Th2 differentiation [13], since activation 
of the ERK pathway is implicated in Th2 differentiation [16].  Our results seem to be 
inconsistent with the previous report [18] that morphine pretreatment inhibits the ERK 
signaling pathway in activated murine T c14-ells.  It may be that the response of T cells to 
morphine differs in different animal species.  On the other hand, suppression of the NF-B 
pathway and IL-2 expression by morphine may result in reduction of the proliferative 
response of T-cells and immune suppression, because IL-2 is known to positively regulate T 
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cell proliferation [23,24].  However, morphine is known to indirectly affect immune-cell 
functions by modulating the release of catecholamines and steroids [8,9], and whether or not 
morphine administration in vivo has the same effects as demonstrated in this study remains to 
be investigated. 
     We have shown that the effects of morphine on ERK phosphorylaion and IL-2 gene 
expression are not antagonized by naloxone.  This suggests that the effect of morphine on the 
ERK pathway and the NF-B pathway is not mediated by opioid receptors.  Several studies 
suggest that immune cells express opioid receptors [4,5], but it is not conclusively known 
whether or not functional opioid receptors are expressed in human T cells.  We examined 
gene expression of three types of opioid receptors, ,  and , in Jurkat T cells, and detected 
only KOR transcript.  However, U50,488, a  receptor-specific agonist, did not enhance 
ERK phosphorylation in activated T cells, suggesting that KOR does not mediate the 
enhancement of ERK phosphorylaion by morphine.  Thus, further study of the receptor 
which mediates the effect of morphine on the ERK signaling pathway is required.  It is 
interesting that the existence of naloxone-insensitive low-affinity morphine binding sites that 
are different from the classical opioid receptors have been reported [6]. 
     We have demonstrated that 1 M of morphine is sufficient to enhance ERK 
phosphorylation in activated T cells, whereas morphine concentration as high as 100 M was 
necessary to suppress IL-2 expression.  The plasma concentration of morphine in clinical 
practice ranges from 25 to 250 nM [29,30].  Morphine at these concentrations may have 
limited effect on ERK phosphorylation and IL-2 expression in activated T cells.  However, it 
is reported that major surgical stress modulates the T cell-mediated immune response [31].  
 17 
Thus, it is possible that morphine influences the alteration of T cell function induced by 
surgical stress in patients undergoing major surgery.  Plasma concentration of morphine 
reaches up to 5 M after high-dose morphine treatment for cancer pain [32].  So it is possible 
that morphine influences the ERK signaling pathway and IL-2 expression during T cell 
activation in patients receiving high-dose morphine treatment. 
     In summary, we have shown that morphine enhanced ERK phosphorylation but inhibited 
IB phosphorylation and IL-2 gene expression in activated human T cells, by a mechanism 
which does not involve known opioid receptors.  These cellular responses might be involved 
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Fig. 1.  Effect of morphine on ERK phosphorylation in CD3+ and Jurkat T cells stimulated 
with anti-CD3 antibody.  CD3+ T cells (A) and Jurkat T cells (B) were incubated in the 
absence or presence of morphine (100 μM) for 24 h, and thereafter stimulated with anti-CD3 
antibody (2 μg/ml) for indicated times.  Phosphorylated ERK and total ERK were detected 
by immunoblot analysis.  Extract from CD3+ T cells stimulated with PMA/Io for 5 min was 
used for positive control.  The upper and lower band in total ERK corresponds to ERK1 and 
ERK2, respectively.  Phosphorylated ERK1 was almost undetectable in T cells stimulated 
with anti-CD3 antibody.  The graphs demonstrate the amount of phosphorylated ERK in 5-
min stimulated cells with or without morphine pretreatment.  Phosphorylated ERK levels are 
normalized to each total ERK level and expressed as percentages of the CD3-stimulated cells 
without morphine pretreatment.  Data are expressed as means ± standard deviations from 5 
separate experiments.  pERK, phosphorylated ERK; tERK, total ERK.  * , P < 0.05 
compared with the CD3-stimulated cells without morphine pretreatment. 
 
Fig. 2.  Effect of morphine on ERK phosphorylation in Jurkat T cells stimulated with 
PMA/Io.  (A) Jurkat T cells were incubated in the absence or presence of morphine (100 
μM) for 24 h and thereafter stimulated with PMA/Io for indicated times.  (B) Jurkat T cells 
were incubated with indicated concentration of morphine for 24 h and followed by stimulation 
with PMA/Io for 5 min.  Phosphorylated ERK and total ERK were detected by immunoblot 
analysis.  The graph demonstrates the amount of phosphorylated ERK in PMA/Io-stimulated 
cells after pretreatment with different concentrations of morphine.  Phosphorylated ERK 
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levels are normalized to each total ERK level and expressed as percentages of the PMA/Io-
stimulated cells without morphine pretreatment.  Data are expressed as means ± standard 
deviations from 5 separate experiments.  pERK, phosphorylated ERK; tERK, total ERK.  * , 
P < 0.05 compared with the PMA/Io-stimulated cells without morphine pretreatment. 
 
Fig. 3.  Morphine itself does not induce ERK phosphorylation in Jurkat T cells.  Jurkat T 
cells were incubated with morphine (100 M) for indicated times, and cell extracts were 
subjected to immunoblot analysis for ERK phosphorylation.  Extract from Jurkat T cells 
stimulated with PMA/Io for 5 min was used for positive control.  pERK, phosphorylated 
ERK; tERK, total ERK. 
 
Fig. 4.  Opioid receptors are unlikely to mediate the effect of morphine on ERK 
phosphorylation in activated T cells.  (A) Jurkat T cells were incubated with indicated 
concentrations of morphine and naloxone for 24 h, and thereafter stimulated with PMA/Io for 
5 min.  Phosphorylated ERK levels are normalized to each total ERK level and expressed as 
percentages of the PMA/Io-stimulated cells without morphine pretreatment.  Data are 
expressed as means ± standard deviations from 5 separate experiments.  (B) RT-PCR 
analysis of total RNA from Jurkat T cells (lane b) and human placenta total RNA (lane c, 
positive control).  Lane a is 1kb DNA Ladder (Promega, Madison, WI).  (C) Jurkat T cells 
were incubated in the absence or presence of U50,488 for 24 h, and thereafter stimulated with 
PMA/Io for 5 min.  Phosphorylated ERK levels are normalized to each total ERK level and 
expressed as percentages of the PMA/Io-stimulated cells without morphine pretreatment.  
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Data are expressed as means ± standard deviations from 5 separate experiments.  pERK, 
phosphorylated ERK; tERK, total ERK.  * , P < 0.05 compared with the PMA/Io-stimulated 
cells without morphine pretreatment.  n.s., no significant difference. 
 
Fig. 5.  Effect of morphine on IκBα phosphorylaion and IL-2 expression in stimulated Jurkat 
T cells.  (A) Jurkat T cells were incubated in the absence and presence of morphine (100 
M) for 24 h and stimulated with PMA/Io for 5 min.  Phosphorylated IκBα and -actin in 
the cell extract were detected by immunoblot analysis.  Phosphorylated IB levels are 
normalized to each -actin level and expressed as percentages of the PMA/Io-stimulated cells 
without morphine pretreatment.  Data are expressed as means ± standard deviations from 5 
separate experiments.  (B, C) Jurkat T cells were incubated with indicated concentration of 
morphine and naloxone for 24 h, and stimulated with PMA/Io for 4 h.  Total RNA was 
subjected to quantitative real-time RT-PCR to determine IL-2 and GAPDH mRNA levels.  
IL-2 mRNA level was normalized to each GAPDH mRNA level.  IL-2 mRNA levels are 
expressed as percentages of the PMA/Io-stimulated cells without morphine pretreatment.  
Data are expressed as means ± standard deviations from 5 separate experiments.  pB, 
phosphorylated IB.  * , P < 0.05 compared with the PMA/Io-stimulated cells without 
morphine pretreatment. 
 
Fig. 6.  Pathways leading to ERK and NF-B activation following TCR stimulation.  The 
figure schematically depicts pathways by which TCR stimulation can lead to ERK and NF-B 
activation. ERK and NF-B have a common upstream signaling pathway involving DAG. 
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Activation of PKC by DAG results in activation of an IB kinase complex (IKK), 
phosphorylation and degradation of IB, and NF-B activation.  Activation of ERK is 
achieved through two different pathways: a pathway through Grb2 and SOS and DAG-PKC-
RasGRP pathway. 






